Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Chronic Pancreatitis II: Pathophysiology01:21

Chronic Pancreatitis II: Pathophysiology

Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Nonalcoholic steatohepatitis and biliary sludge in people with metabolic syndrome].

Terapevticheskii arkhiv·2016
Same author

[COURSE OF BILIARY SLUDGE ON THE BACKGROUND NON-ALCOHOLIC FATTY LIVER DISEASE].

Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology·2016
Same author

[CHANGES IN MICROBIOCENOSIS OF THE COLON IN PATIENTS WITH CHRONIC LIVER DISEASE AND LATENT HEPATIC ENCEPHALOPATHY].

Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology·2016
Same author

[NONALCOHOLIC FATTY LIVER DISEASE: DIAGNOSTIC, SYMPTOMS, TREATMENT. GUIDELINES WERE APPROVED BY THE XV GASTROENTEROLOGICAL SCIENTIFIC SOCIETY OF RUSSIA IN 2015].

Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology·2016
Same author

[AUTOIMMUNE LIVER DISEASES: CLINICAL FEATURES, DIAGNOSIS, TREATMENT. GUIDELINES WERE APPROVED BY THE XV GASTROENTEROLOGICAL SCIENTIFIC SOCIETY OF RUSSIA IN 2015].

Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology·2016
Same author

[GUIDELINES FOR DIAGNOSIS AND TREATMENT OF CELIAC DISEASE].

Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology·2015
Same journal

[CONGENITAL MALFORMATION: BILIARY ATRESIA].

Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology·2018
Same journal

[ASYMPTOMATIC INTRAHEPATIC CHOLANGIOCARCINOMA].

Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology·2018
Same journal

[HEREDITARY HEMOCHROMATOSIS (clinical observations)].

Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology·2018
Same journal

[STAGING SYSTEMS OF HEPATOCELLULAR CARCINOMA].

Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology·2018
Same journal

[COMPARATIVE EXPERIMENTAL EVALUATION OF THE EFFECTIVENESS OF MODERN PROBIOTICS, PREBIOTICS, SYNBIOTICS AND METABIOTICS FOR CORRECTION OF INTESTINAL MICROBIOCENOSIS IN ANIMALS WITH ANTIBIOTIC-ASSOCIATED DYSBIOSIS].

Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology·2018
Same journal

[METABOLIC CORRECTOR WITH HEPATOPROTECTIVE PROPERTIES RUNIHOL®: FROM SCREENING TO CLINICAL TESTING].

Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology·2018
See all related articles

Related Experiment Video

Updated: May 14, 2026

Histological Analyses of Acute Alcoholic Liver Injury in Zebrafish
10:45

Histological Analyses of Acute Alcoholic Liver Injury in Zebrafish

Published on: May 25, 2017

[Alcoholic hepatitis].

V G Radchenko, E M Prikhod'ko

    Eksperimental'Naia I Klinicheskaia Gastroenterologiia = Experimental & Clinical Gastroenterology
    |February 14, 2013
    PubMed
    Summary
    This summary is machine-generated.

    Kholit aids in treating alcoholic hepatitis by improving patient condition and normalizing health indicators. This study shows Kholit

    More Related Videos

    Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
    11:36

    Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

    Published on: May 29, 2020

    Related Experiment Videos

    Last Updated: May 14, 2026

    Histological Analyses of Acute Alcoholic Liver Injury in Zebrafish
    10:45

    Histological Analyses of Acute Alcoholic Liver Injury in Zebrafish

    Published on: May 25, 2017

    Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
    11:36

    Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

    Published on: May 29, 2020

    Area of Science:

    • Hepatology
    • Gastroenterology
    • Pharmacology

    Background:

    • Alcoholic hepatitis is a severe liver condition.
    • Effective treatment strategies are crucial for patient outcomes.

    Purpose of the Study:

    • To assess the efficacy of Kholit as part of a comprehensive treatment for alcoholic hepatitis.

    Main Methods:

    • A study involving 72 patients diagnosed with chronic alcoholic hepatitis.
    • A subgroup of 37 patients received complex treatment including Kholit.

    Main Results:

    • Kholit administration led to enhanced general patient well-being.
    • Objective disease markers showed improvement.
    • Laboratory and instrumental data indicated normalization.

    Conclusions:

    • Kholit demonstrates significant benefits in the complex management of alcoholic hepatitis.
    • It contributes to the recovery and stabilization of patients with this condition.